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Abstract
Detecting mutations in single cells from cancer specimens is now a major area of translational research. In a
recent article in this journal, Khalique et al validated an immunohistochemistry assay for ARID1A that reliably
identifies loss of function mutations in single cells in tissue sections. This work exemplifies best practice for
developing and orthogonally validating immunohistochemical assays to provide clearly interpretable mutational
results with spatial context.
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The reputation of immunohistochemistry assays
(IHC) as biomarkers for precision medicine is not
the best. There is an impression in some quarters
that interpreting different shades of brown is like
reading tea leaves. Clinical IHC has been around for
decades [1]—so why do we have such a jaundiced
view of its value for clinical biomarkers? Incompre-
hensibly, there is still wide use of low-specificity
antibodies and poorly standardized assays, resulting
in variable biological and clinical signals. Over
20 000 publications using IHC are published each
year and the majority should probably have never
seen the light of day [2]. By contrast, in a recent
article in this journal Khalique and colleagues dem-
onstrate what is needed to turn research-grade IHC
into a clinically useful assay for detecting mutations
in ARID1A [3].
Their study rigorously validates three different
ARID1A (AT-rich interactive domain-containing pro-
tein 1A; also called BAF250a) antibodies using an
automated, standardized assay against the gold stan-
dard of next-generation sequencing to detect ARID1A
loss of function mutations. Staining from all three anti-
bodies shows (almost) perfect agreement with very
high concordance between loss of ARID1A expression
and detection of predicted loss of function ARID1A
mutations.
This finding is of immediate clinical relevance for
diagnostic questions such as distinguishing clear cell
and endometrioid histotypes of ovarian or endometrial
carcinomas from histotypes in which ARID1A alter-
ations do not occur [4,5]. While the prognostic value
of ARID1A mutation is controversial, even contradic-
tory, this well validated assay now enables large-scale
studies to definitively test prognostic utility [6]. Look-
ing forward, there is increasing clinical interest in the
development of synthetic-lethal treatments with loss of
function of ARID1A mutations across a broad spec-
trum of tumors [7–9]. The results from Khalique and
colleagues now provide a robust biomarker for clinical
trial inclusion and potentially a predictive biomarker
for future therapies.
The history of ARID1A as a cancer-relevant gene is
relatively short. In 2010, two groups simultaneously
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identified recurrent ARID1A mutations in slightly less
than half of endometriosis-associated clear cell [10,11]
and endometrioid ovarian carcinomas [10]. Since then,
ARID1A mutations have been detected in many cancer
types including endometrial endometrioid and clear
cell carcinomas, urinary bladder carcinomas, Hodgkin
lymphoma, gastroesophageal, colorectal and hepato-
biliary carcinomas among others [12]. ARID1A
encodes one component of the SWI/SNF chromatin
remodeling complex that facilitates target-specific
DNA binding and regulation of transcription by repo-
sitioning nucleosomes [6]. Cancers with alterations in
the SWI/SNF chromatin remodeling complex are not
sensitive to conventional chemotherapy and have dis-
tinct clinical features [13,14]. Co-inactivation of
ARID1A and its paralog ARID1B give rise to particu-
larly aggressive dedifferentiated endometrial and ovar-
ian endometrioid carcinomas [15] and mutations in
another SWI/SNF component SMARCA4 causes lethal
small cell carcinoma of the ovary [16–19]. ARID1A-
targeted therapies are now in clinical development
with trials focusing on cancers with loss of function
ARID1A mutations (NCT02059265, NCT03297424;
see https://clinicaltrials.gov/).
Although DNA sequencing is the gold standard for
detecting ARID1A mutations, nonsequencing-based
assays still have important clinical utility. Firstly, next-
generation sequencing of ARID1A has been difficult
owing to its large size and high GC content in exon
1. Secondly, the implementation of an IHC based test
(once properly validated) has fewer barriers to imple-
mentation as the infrastructure required is inexpensive
and has ISO accreditation in most pathology centers.
The origins of IHC can be traced back to the 1930s
[20,21] but wider clinical adoption had to wait until
the 1980s, enabled by commercial-scale production of
monoclonal antibodies and other refinements allowing
use of formalin-fixed paraffin embedded tissue [1].
Publications from the 1990s then showed that IHC
could be used to identify mutant p53 [22]. However, it
was not until very recently that an IHC assay could
provide near-perfect accuracy in predicting TP53
mutation status [23]. Advancements have depended on
3 main factors: first, significantly improved sensitivity
and specificity by using higher affinity rabbit monoclo-
nal antibodies and newer polymer-based detection sys-
tems with increased signal amplification. Second,
robust standardization of experimental conditions from
improved automated staining platforms. Third,
improvements in interpretation by mandating use of
normal cells as intrinsic controls for judging loss of
protein expression [23]. This has enabled sophisticated
interpretation of abnormal p53 staining that maps the
different classes of TP53 mutations to their functional
consequences (Table 1).
There are limitations to the ARID1A IHC assay
from Khalique and colleagues that should be kept in
mind. First, while most ARID1A mutations are loss of
function mutations, there are a number of recurrent
missense mutations that may impair ARID1A func-
tion, but do not appear to change protein expression.
For a clinical trial, using only IHC could result in con-
tamination of ARID1A-competent trial populations.
The extent to which IHC could miss deleterious
ARID1A missense mutations is unknown and requires
further study.
Second, ARID1A loss can be subclonal, indicating a
later mutational event during tumor evolution. Tempo-
ral modeling of endometrial endometrioid carcinomas
showed that only a portion of ARID1A mutations were
truncal [24]. Subclonal ARID1A mutations are com-
mon in mismatch repair deficient (MMR-D) cancers
because ARID1A has numerous short mononucleotide
repeats that have a high chance of slippage errors
(Figure 1) [25,26]. In such cases, convergent evolution
of different ARID1A alterations resulting in phenotypi-
cally indistinguishable but mechanistically distinct loss
of ARID1A protein can occur [24].
Subclonal loss may also be critical in identifying
premalignant lesions. In the example of endometriosis,
malignant transformation is rare and no biomarkers
exist to distinguish “premalignant” endometriosis from
the much more common chronic disease. A handful of
studies have implicated subclonal loss of ARID1A
immunoreactivity in endometriosis without co-existing
cancer (i.e. loss in only a subset of endometriosis
glands and/or loss limited to contiguous epithelium
Table 1. Correlation of p53 immunohistochemical phenotype with
TP53 genotype
p53 staining pattern Interpretation TP53 mutation status

















Cytoplasmic (uncommon) Mutant Loss of function mutation
disrupting nuclear
localization domain
*with the exception of truncating or splicing TP53 mutations that may result
in wild type IHC staining observed in 2–4% of tubo-ovarian high-grade serous
carcinomas.
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within a gland) [27–29]—although validation of these
findings with orthogonal sequencing data is very lim-
ited [30]. Now that we have high quality IHC tools,
there is certainly sufficient justification for larger scale
investigation of ARID1A loss (and mutation) in endo-
metriosis, particularly if cohorts can be identified where
progression to cancer has occurred. A clear understand-
ing of how to interpret heterogeneous/subclonal
ARID1A staining will undoubtedly accelerate such
studies.
Finally, the mechanisms explaining total loss of
ARID1A protein are still elusive. Unlike TP53, loss of
heterozygosity at the ARID1A locus has not been
widely reported, and at least for clear cell and
endometrioid ovarian carcinomas, does not appear to
be common [31,32]. In the cohort by Khalique and
colleagues 8/45 (18%) cases harbored more than one
ARID1A mutation and similar rates (6/27; 22%) have
previously been reported [32]. Systematic analyses are
required to validate whether (or when) both alleles are
affected and to rule out alternative possibilities, such
as the presence of two co-existing subclones carrying
unique alterations.
Despite these caveats, the report from Khalique and
colleagues suggests that ARID1A IHC can reliably
detect loss of function mutations and is ready to be
accepted as a clinical-grade test. A categorical scoring
system should now be agreed upon to distinguish
Figure 1. (A) H&E photomicrograph of endometrial endometrioid carcinoma, grade 3; (B) absence of MSH6 suggesting mismatch repair
deficiency (additional MSH2 absence not shown). The arrow shows positive internal control stromal staining; (C) small focus of subclonal
ARID1A loss (asterisk); (D) focus of p53 overexpression overlying but extending beyond the ARID1A focus (asterisk). Taken together these
panels suggest a prototypical somatic mismatch repair deficiency resulting in subclonal TP53 missense alteration, and subsequent
ARID1A loss of function mutation.
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between normal retained/present ARID1A expression
and abnormal/absent expression, and whether this is
complete or subclonal. As for p53 IHC, ARID1A IHC
has the potential to achieve near-single-cell resolution
for detecting mutations whilst also providing detailed
information about the spatial context of mutated cells.
IHC based prediction of ARID1A mutation now joins a
small and exclusive group of well-validated and clini-
cally useful predictive IHC biomarkers.
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